Trial · NCT06863571
Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke
NCT06863571, Phase 3, Recruiting, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke. Trials, record NCT06863571. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06863571
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke
- NCT number
- NCT06863571
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 68 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Ischemic Stroke
- Interventions
- PPA Intervention
- First posted
- 2025-03-07
- Last updated
- 2025-04-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cerebral Edema at 5-7 Days | 5-7 days post-treatment | The primary outcome of this study is cerebral edema. Edema will be quantified using standardized imaging analysis techniques. The difference in cerebral edema between the PPA intervention group and the standard treatment group will be compared to evaluate the efficacy of the pharmacological cocktail in reducing brain swelling. |
| Secondary | 90-Day Functional Outcome (Modified Rankin Scale, mRS) | 90 days post-treatment | Functional outcomes will be assessed using the modified Rankin Scale (mRS) at 90 days post-treatment, mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome |
| Secondary | Incidence of Hypotension During the Treatment Period | During the 5-day treatment period | The occurrence of clinically significant hypotension (defined as systolic blood pressure \<90 mmHg) will be monitored throughout the intervention period. The frequency, severity, and need for medical intervention will be compared between the two study groups. |
| Secondary | Need for Decompressive Craniectomy | Up to 7 days post-treatment | The proportion of patients who require decompressive craniectomy (DC) due to worsening cerebral edema and refractory intracranial hypertension will be recorded and compared between the study groups. This will serve as an indicator of treatment efficacy in preventing severe brain swelling. |
| Secondary | Mortality at 90 Days | 90 days post-treatment | All-cause mortality will be recorded and compared between the PPA intervention and standard treatment groups to evaluate the impact of the intervention on survival. |
| Secondary | Incidence of Serious Adverse Events (SAEs) | Up to 90 days post-treatment | All serious adverse events (SAEs), including cardiovascular complications, major bleeding, and severe drug reactions, will be recorded and compared between groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06863571
GET https://conductscience.org/api/trials/v1/NCT06863571/registered